Use of cardamonin in treatment of aortic valve calcification

A technology for aortic and calcified diseases, applied in the direction of cardiovascular system diseases, ketone active ingredients, drug combinations, etc., can solve the problems of increasing the financial burden of patients' families, high perioperative mortality, and poor long-term effects

Active Publication Date: 2021-04-09
HUBEI UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, surgery will inevitably bring higher risks to patients, such as high perioperative mortality rate, poor long-term effect, and at the same time increase the financial burden on patients' families. There are still many clinical trials to verify some promising pharmacological interventions that stop or slow its progression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cardamonin in treatment of aortic valve calcification
  • Use of cardamonin in treatment of aortic valve calcification
  • Use of cardamonin in treatment of aortic valve calcification

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1. Construction of a human valve mesenchymal cell calcification model induced by a commercial osteogenic induction medium

[0026] Human valve mesenchymal cells with a culture density close to 80% were starved overnight with 2% FBS+DMEM high-sugar medium, and then starved with a newly configured osteogenic induction medium (Cyagen, product number: HUXMA-90021). The calcification of the valvular interstitial cells was induced, and alizarin red staining was performed after 21 days of induction to investigate the effects of different treatments on the calcification of the valvular interstitial cells.

Embodiment 2

[0027] Embodiment 2, Cardamonin inhibits calcification of human valve interstitial cells

[0028] The human valve interstitial cell calcification model constructed as in Example 1 above was adopted, and the human valve interstitial cells were divided into 3 groups, respectively control group (untreated, normal medium), OM group (osteogenic medium induction) and OM+CDM group (cardamonin was added after osteogenic medium induction). Different concentrations of cardamonin (cardamonin (CAS: 18956-16-6) purchased from Selleck, catalog number: S3942) were used to treat human valve interstitial cells, and IC50 test, CCK8 determination and Alizarin red staining analysis were performed.

[0029] In order to evaluate the cytotoxicity of CDM to hVIC, IC50 test was carried out, and the results showed that CDM had obvious cytotoxicity to hVIC when the concentration exceeded 10 μM ( figure 1 b). Therefore, 10 μM of CDM was used in all subsequent in vitro experiments. In the detection of ...

Embodiment 3

[0030] Example 3, cardamomine inhibits human valve interstitial cell calcification gene protein expression

[0031]The human valve interstitial cell calcification model constructed as in Example 1 above was adopted, and the human valve interstitial cells were divided into 3 groups, respectively control group (untreated, normal medium), OM group (osteogenic medium induction) and OM+CDM group (cardamonin was added after osteogenic medium induction). Human valve mesenchymal cells were treated with 10 μM cardamonin at a final concentration (final concentration in culture medium), and osteogenesis-related genes RUNX2, ALP, OPN, BMP2, SPP1, TNF-α, COL1A2 (type I collagen) were detected at 24h and 48h ).

[0032] Quantitative qRT-PCR results showed that compared with the control group, the expressions of RUNX2, BMP2, SPP1, TNF-α, and COL1A2 in hVIC were significantly up-regulated in the OM group at 24h and 48h (*p figure 2 a and 2b). Similar to the above, the expression of protein ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of prevention and / or treatment of aortic valve calcification, and the inventor has found through research that cardamonin can be used to effectively down-regulate protein expression of ALP, RUNX2, BMP2, OPN, TNF-alpha and I-type collagen (COL1) in valvular interstitial cells, and inhibit calcification of valvular interstitial cells, so as to inhibit or delay calcification of valves. The invention further provides an application of cardamonin in preparation of a medicine for preventing and / or treating aortic valve calcification of an individual. According to the invention, a new choice is provided for treating the aortic valve calcification by adopting a non-surgical method.

Description

technical field [0001] The invention relates to the field of prevention and / or treatment of aortic valve calcification, in particular to the use of cardamonin in the prevention and / or treatment of aortic valve calcification. Background technique [0002] Cardamonin (CDM) is a chalcone belonging to the flavonoid family, which can be isolated from various herbs such as galangal, pecan, ginkgo, and Jiaogulan. It has various pharmacological effects, such as anti-inflammatory, anti-tumor, anti-fungal and antioxidant effects. However, there is no report on the relationship between cardamonin and aortic valve calcification. [0003] Calcification refers to a process in which a certain tissue in the human body undergoes necrosis under the action of some factors, and then calcium salts in the body are deposited in the necrotic focus, making the lesion localized and tending to a stable process. In essence, calcification is a defensive response of the body to lesions, which is conduc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/12A61P9/00
CPCA61K31/12A61P9/00
Inventor 许康刘艳菊刘先琼瞿领航曹国胜王光忠
Owner HUBEI UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap